Head of Faculty of Biochemistry, Biophysics and Medical Biotechnology Jagiellonian University in Krakow, Poland
Prof Jozef Dulak, PhD, DSc, is the head of Department of Faculty of Biochemistry, Biophysics and Medical Biotechnology Jagiellonian University in Krakow, Poland. He obtained his PhD (1990) and DSc (2001) (habilitation) from Jagiellonian University. He is a doctor honoris causa of the University of Orleans, France (2012) and a corresponding member of the Polish Academy of Arts and Sciences (elected in 2011). He is also a member of the Committee of Biochemistry and Biophysics of Polish Academy of Science and the Committee of Biotechnology. Prof. Dulak is also a member of the Committee for Evaluation of Scientific Institutions (KEJN) at the Ministry of Science and Higher Education. ). Prof. Dulak was a member of the Scientific Committee of the Innovative Medicines Initiative in Brussels (since 2008).
Prof. Dulak and his team have organized the 6th European Meeting for Vascular Biology and Medicine, which has been held in Krakow from 21 to 24 September 2011 and gathered 313 participants from 23 countries ( http://emvbm2011.org/en). The abstracts of the conference have been published in Vascular Pharmacology, and the special issue of that journal http://www.sciencedirect.com/science/journal/15371891 as well as double issue of Thrombosis and Haemostasis (vol 108/3 and a08/5) have been published in 2012 with the papers presented during the meeting.
His research interest include stem cell biology, vascular biology and medicine, gene and cell therapy, cancer biology, microRNAs, inflammation and oxidative stress-driven mechanisms of diseases. He has co-authored more than 120 papers, has held many research grants and is currently coordinating several new ones.
Prof. Dulak was a visiting professor of University of Orleans, France (2008/2009) and of Japanese Society for the Promotion of Science (2010). He has been an organizer and co-organizer of several international conferences. Prof. Dulak is a member of the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology, Vascular Cell and Folia Biologica.
Vascular biology comprises the research performed by basic and clinical scientists what
should help to translate the results into the clinical application. Nowadays such a goal can be achieved only by extensive collaboration between various groups, sharing their knowledge, expertise and tools. I see the EVBO as a society which will help scientists and clinicians to really benefit from such interactions. Integration of science in united Europe requires many different platforms, not because of the unrestrained need to multiply various entities, but due to the enlarging complexity of our research. I believe that EVBO will be such a melting pot in which young scientists can benefit from the knowledge of the more experienced colleagues and all can gain the fruits of real European collaboration.